港股创新药大爆发，主线行情回归？高弹性港股通创新药ETF（520880）猛涨4.66%，技术面现“定海神针”！

Group 1 - The Hong Kong stock market for innovative drugs experienced a significant surge, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising by 5.31%, outperforming the Hang Seng Index and other related indices [1] - Major stocks leading the rally included 3SBio, which surged by 10.18%, and BeiGene, which rose by 7.71%, reaching a nearly four-year high [1] - The ETF recorded a trading volume of 588 million yuan, indicating strong investor interest [1] Group 2 - Technical indicators show a strong bullish signal for the Hong Kong Stock Connect Innovative Drug ETF, with a significant increase in buying pressure and a MACD indicator suggesting a trend reversal [2] - Citic Securities forecasts continued over-allocation to the pharmaceutical sector through 2026, while Dongwu Securities identifies innovative drugs as a key investment theme for the same period [3] Group 3 - BeiGene's impressive performance, with a net profit of 1.139 billion yuan in the first three quarters, has positively influenced industry expectations [4] - The introduction of a new payment channel for high-priced innovative drugs through commercial insurance in the 2025 national medical insurance negotiations is expected to enhance cash flow for pharmaceutical companies [4] - The total value of outbound licensing transactions for Chinese innovative drugs exceeded 100 billion USD in the first ten months of 2025, highlighting the global competitiveness of Chinese pharmaceutical companies [4] Group 4 - The Hong Kong Stock Connect Innovative Drug ETF (520880) is recommended for investment, with its index comprising primarily innovative drug companies, excluding CXO firms [4][5] - The top ten innovative drug companies account for over 71% of the ETF's weight, indicating a strong focus on leading firms in the sector [5] - The ETF's design includes measures to control risks associated with less liquid stocks, enhancing overall risk management [6]